Treatment for Smallpox Gets FDA Priority Review

The development of TPOXX was aided by funding from the Biomedical Advanced Research and Development Authority
The development of TPOXX was aided by funding from the Biomedical Advanced Research and Development Authority

The Food and Drug Administration (FDA) has accepted and granted priority review to the New Drug Application (NDA) for TPOXX, an antiviral therapy for smallpox. There is currently no treatment approved for smallpox infection. 

TPOXX (tecovirimat; SIGA Technologies) is a novel small molecule orally-administered antiviral. The treatment was developed under the FDA's ‘Animal Rule' where efficacy is determined in animal studies and human studies determine safety and appropriate dosing. 

“Our public-private collaboration serves as an important example of how such partnerships can advance novel drugs for unmet medical needs,” said Dr. Phil Gomez, CEO of SIGA. “Eventual approval of this product would be an important step in advancing health security against the serious threat of a potential smallpox-based bioterror attack.” 

Related Articles

SIGA received funding to complete the development of TPOXX from the U.S. government's Biomedical Advanced Research and Development Authority (BARDA). Although not yet approved, BARDA has already purchased 2 million courses of TPOXX, which have been delivered to the Strategic National Stockpile (SNS).

The FDA has stated a target action date for TPOXX of August 8, 2018.

For more information visit SIGA.com.